<DOC>
	<DOCNO>NCT02688348</DOCNO>
	<brief_summary>This research trial study quality life bladder-preservation chemotherapy radiation therapy ( chemo-radiotherapy ) patient bladder cancer spread muscle layer bladder ( muscle-invasive bladder cancer ) . Bladder-preservation chemo-radiotherapy standard treatment patient muscle-invasive bladder cancer , however , chemo-radiotherapy may cause urinary tract , bowel , sexual late side effect negatively affect patient ' quality life . Studying quality-of-life patient muscle-invasive bladder cancer chemo-radiotherapy may help identify long-term side effect treatment may help plan best treatment future improve patient ' quality life .</brief_summary>
	<brief_title>Quality Life After Bladder-Preservation Chemotherapy Radiation Therapy Patients With Muscle-Invasive Bladder Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To study health-related quality life ( HRQoL , QOL ) patient undergo protocol-based bladder-preservation chemo-radiation . OUTLINE : Patients complete European Organization Research Treatment Cancer ( EORTC ) QLQ-Bladder Cancer Muscle Invasive ( BLM-C30 ) baseline , every 3 month 1 year , every 4 month 1 year , every 6 month 3 year , annually thereafter completion chemo-radiotherapy .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<criteria>Histologically confirm muscleinvasive urothelial cancer ( histology exclude ) No pelvic nodal metastasis distant metastasis ( base compute tomography [ CT ] , positron emission tomography [ PET ] magnetic resonance image [ MRI ] ) Karnofsky performance status ( KPS ) &gt; = 70 Ability understand , willingness sign , write informed consent Patient either opt bladdersparing treatment compare radical cystectomy , deem medically inoperable Following recent recommendation International Consultation Urological DiseasesEuropean Association Urology International Consultation Bladder Cancer , eligible patient hydronephrosis , extensive carcinoma situ ( CIS ) , tumor invasion stroma prostate Patients evidence distant metastasis Prior pelvic radiotherapy History Crohn 's disease ulcerative colitis Unable receive chemotherapy Histologies urothelial ( eg . squamous cell carcinoma , adenocarcinoma , small cell )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>